Investor Relations

SEC Filings

Form 10-K
ALTIMMUNE, INC. filed this Form 10-K on 04/01/2019
Document Outline
Entire Document (8719.8 KB)
Subdocument 1 - 10-K - 10-K
Page 1 - UNITED STATES
Page 2 - ALTIMMUNE, INC.
Page 3 - PART I
Page 4 - We have based the forward-looking statements included in this Annual Report on information available
Page 5 - NasoVAX
Page 6 - Our Strategy
Page 7 - Competition
Page 8 - Patent Rights Related to our RespirVec Platform Technology
Page 9 - Patent Rights Related to Our Densigen Platform Technology
Page 10 - NasoShield and SparVax-L, Anthrax Vaccines
Page 11 - BARDA Anthrax Contract
Page 12 - NIAID Anthrax Contract
Page 13 - N/A
Page 14 - in vitro
Page 15 - Post-Approval Requirements
Page 16 - Animal Rule and Project BioShield Emergency Use Authorization
Page 17 - FDA Expedited Development and Approval Programs
Page 18 - U.S. Regulations Affecting Certain Federally Funded Programs, such as Medicare and Medicaid
Page 19 - U.S. Health Care Reform Law
Page 20 - Environmental Regulations
Page 21 - Clinical Trial Authorization in the European Union
Page 22 - Consultation with the European Medicines Agency
Page 23 - The Marketing Authorization Application: Contents and Approval Standard
Page 24 - Other Jurisdictions
Page 25 - Financial Information by Geographic Area
Page 26 - We have incurred significant losses since our founding and anticipate that we will continue to incur
Page 27 - Future conditions might require us to make substantial write-downs in our assets, which would advers
Page 28 - Raising additional capital may cause dilution to the Company s stockholders, restrict our operations
Page 29 - Because our product candidates are in an early stage of development, there is a high risk of failure
Page 30 - We may encounter substantial delays in our clinical trials, or our clinical trials may fail to demon
Page 31 - We may find it difficult to enroll patients in our clinical trials, which could delay or prevent cli
Page 32 - It may be difficult to predict the time and cost of product development. Unforeseen problems may pre
Page 33 - We face substantial competition from other pharmaceutical and biotechnology companies, which may res
Page 34 - If we fail to attract and keep senior management and key scientific personnel, we may be unable to s
Page 35 - Risks Related to the Regulatory Approval Process
Page 36 - If we fail to obtain regulatory approval in non-U.S. jurisdictions, we will not be able to market ou
Page 37 - If the FDA or comparable foreign regulatory authorities approve generic or biosimilar versions of an
Page 38 - N/A
Page 39 - Risks Related to Our Intellectual Property
Page 40 - We may not be able to protect our intellectual property rights throughout the world.
Page 41 - We may become involved in lawsuits to protect or enforce our intellectual property, which could be e
Page 42 - We may be subject to claims that our employees, independent contractors or consultants have wrongful
Page 43 - Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure
Page 44 - We rely on, and expect to continue to rely on, third parties to manufacture our product candidates a
Page 45 - If we are unable to manufacture our products in sufficient quantities, or at sufficient yields, or a
Page 46 - If we are unable to establish sales, marketing and distribution capabilities, we may not be successf
Page 47 - We may not be successful in establishing and maintaining strategic partnerships, which could adverse
Page 48 - A breakdown in our information technology systems could result in a significant disruption to our bu
Page 49 - Risks Related to the Company s BARDA Contract and Other Government Programs
Page 50 - Most of our immediately foreseeable future revenues are contingent upon grants, contracts and loans
Page 51 - The U.S. government s determination to award any contracts may be challenged by an interested party,
Page 52 - Laws and regulations affecting government contracts make it more costly and difficult for us to succ
Page 53 - Price controls may be imposed, which may adversely affect our future profitability.
Page 54 - The impact of recent health care reform legislation and other changes in the health care industry an
Page 55 - Certain business practices associated with the commercialization of pharmaceutical products are subj
Page 56 - N/A
Page 57 - We must comply with data privacy and security laws and regulations, and failure to comply with these
Page 58 - Our employees, independent contractors, principal investigators, consultants, commercial partners an
Page 59 - We are required to comply with certain export control laws which may limit our ability to sell our p
Page 60 - Future sales and issuances of our common stock or rights to purchase common stock could result in su
Page 61 - If we do not meet the continued listing standards of The NASDAQ Global Market our common stock could
Page 62 - PART II
Page 63 - Item 7. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 64 - NasoShield
Page 65 - Reverse Stock-Split
Page 66 - N/A
Page 67 - Current Resources
Page 68 - General and Administrative Expenses
Page 69 - Business combination
Page 70 - Fair Value Measurements
Page 71 - Income Taxes
Page 72 - Results of Operations
Page 73 - Research and Development Expenses
Page 74 - Other Income (Expense)
Page 75 - Liquidity and Capital Resources
Page 76 - Cash Flows
Page 77 - Item 8. Financial Statements and Supplementary Data.
Page 78 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 79 - ALTIMMUNE, INC.
Page 80 - ALTIMMUNE, INC.
Page 81 - ALTIMMUNE, INC.
Page 82 - ALTIMMUNE, INC.
Page 83 - ALTIMMUNE, INC.
Page 84 - Guarantees and Indemnifications
Page 85 - Business Combination
Page 86 - Fair Value Measurements
Page 87 - Financial Instruments
Page 88 - Accounts Receivable
Page 89 - Warrants
Page 90 - Income Taxes
Page 91 - N/A
Page 92 - N/A
Page 93 - N/A
Page 94 - N/A
Page 95 - N/A
Page 96 - N/A
Page 97 - University of Alabama at Birmingham Research Foundation
Page 98 - Line of Credit
Page 99 - N/A
Page 100 - N/A
Page 101 - N/A
Page 102 - N/A
Page 103 - N/A
Page 104 - Stock Options
Page 105 - Expected volatility:
Page 106 - Expected dividend yield:
Page 107 - Stock-based Compensation Expense
Page 108 - N/A
Page 109 - Operating Leases
Page 110 - Other Contingencies
Page 111 - N/A
Page 112 - Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
Page 113 - PART III
Page 114 - Philip L. Hodges
Page 115 - Will Brown, CPA
Page 116 - Board committees
Page 117 - Code of Business Conduct and Ethics and other governance documents
Page 118 - Report of the Audit Committee the Board of Directors
Page 119 - Item 11. Executive Compensation.
Page 120 - 401(k) Plan
Page 121 - Employment Agreement with Vipin K. Garg, Ph.D.
Page 122 - Consulting Agreement with Will Brown, CPA
Page 123 - Outstanding Equity Awards at 2018 Fiscal Year-End
Page 124 - Director Compensation
Page 125 - N/A
Page 126 - Equity Compensation Plan Information
Page 127 - Review and approval of related party transactions
Page 128 - Pre-Approval Policies
Page 129 - PART IV
Page 130 - N/A
Page 131 - N/A
Page 132 - Financial Statements and Schedules of Subsidiaries and Affiliates
Page 133 - SIGNATURES
Subdocument 2 - EX-21 - EX-21
Page 1 - N/A
Subdocument 3 - EX-23.1 - EX-23.1
Page 1 - N/A
Subdocument 4 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 5 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 6 - EX-32.1 - EX-32.1
Page 1 - N/A
Subdocument 7 - EX-32.2 - EX-32.2
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer